{"id":4195,"date":"2025-03-31T18:12:00","date_gmt":"2025-03-31T18:12:00","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/metolazone-txt\/"},"modified":"2025-03-31T18:12:00","modified_gmt":"2025-03-31T18:12:00","slug":"metolazone-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/metolazone-txt\/","title":{"rendered":"Metolazone.txt"},"content":{"rendered":"<p><H3>  CLINICAL USE <\/H3><br \/>\nThiazide diuretic, acts synergistically with loop diuretics:Oedema Hypertension <H3> DOSE IN NORMAL RENAL FUNCTION  <\/H3>Oedema: 5\u201310 mg, increased to 20 mg  daily; maximum 80 mg dailyHypertension: 5 mg initially; maintenance:  5 mg on alternate days<H3>  PHARMACOKINETICS    <\/H3><LI> Molecular weight &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :365.8<\/li>\n<li>  %Protein binding  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp  &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :95<\/li>\n<li>  %Excreted unchanged in urine &amp;nbsp &amp;nbsp : 80\u201395<\/li>\n<p><LI> Volume of distribution (L\/kg) &amp;nbsp &amp;nbsp &amp;nbsp :1.6<\/li>\n<p><LI>half-life \u2013 normal\/ESRD (hrs)&amp;nbsp &amp;nbsp &amp;nbsp :8\u201310\/\u2013<H3>  DOSE IN RENAL IMPAIRMENT <\/H3> <H4>GFR (mL\/MIN)<\/H4><LI> 20 to 50  &amp;nbsp &amp;nbsp : Dose as in normal renal function <LI> 10 to 20  &amp;nbsp &amp;nbsp : Dose as in normal renal function <LI> &lt;10 &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp : Dose as in normal renal function<H3> DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES  <\/H3><LI> CAPD  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp:Unlikely to be dialysed. Dose as in normal renal function <\/p>\n<li> HD &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :Not dialysed. Dose as in normal renal function <LI>HDF\/high flux  &amp;nbsp :Unknown dialysability. Dose as in normal renal function<LI>CAV\/VVHD  &amp;nbsp &amp;nbsp &amp;nbsp:Not Dialysed. Dose as in normal renal function<H3> IMPORTANT DRUG INTERACTIONS  <\/H3>Potentially hazardous interactions with other drugs\n<li>Analgesics: increased risk of  nephrotoxicity with NSAIDs; antagonism of diuretic effect\n<li>Anti-arrhythmics: hypokalaemia leads  to increased cardiac toxicity; effects of lidocaine and mexiletine antagonised\n<li>Antibacterials: avoid administration with  lymecycline\n<li>Antidepressants: increased risk of  hypokalaemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclics\n<li>Anti-epileptics: increased risk of  hyponatraemia with carbamazepine\n<li>  Antifungals: increased risk of  hypokalaemia with amphotericinAntihypertensives: enhanced hypotensive  effect; increased risk of first dose hypotension with post-synaptic alpha-blockers like prazosin; hypokalaemia increases risk of ventricular arrhythmias with sotalol\n<li>Antipsychotics: hypokalaemia increases  risk of ventricular arrhythmias with amisulpride or sertindole; enhanced hypotensive effect with phenothiazines; hypokalaemia increases risk of ventricular arrhythmias with pimozide \u2013 avoid concomitant use\n<li>Atomoxetine: hypokalaemia increases risk  of ventricular arrhythmiasCardiac glycosides: increased toxicity if  hypokalaemia occurs\n<li>Ciclosporin: increased risk of  nephrotoxicity and possibly hypomagnesaemiaLithium excretion reduced, increased  toxicity<H3> ADMINISTRATION  <\/H3><H4> Reconstition<\/H4>\u2013<H4>  Route  <\/H4>Oral <H4>  Rate of Administration  <\/H4>\u2013<H4>Comments<\/H4>\u2013<H4>  OTHER INFORMATION  <\/H4>May result in profound diuresis. Monitor  patient\u2019s fluid balance carefullyMonitor for hypokalaemia In patients with creatinine clearance less  than 50 mL\/minute there is no clinical evidence of accumulation.<br \/>\n","protected":false},"excerpt":{"rendered":"<p>CLINICAL USE Thiazide diuretic, acts synergistically with loop diuretics:Oedema Hypertension<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4195","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4195"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4195\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}